← All companies

ACHV

Achieve Life Sciences, Inc.

ACHV Nasdaq In Vitro & In Vivo Diagnostic Substances EDGAR ↗

$6.32

+0.02 +0.32%

Key statistics

from XBRL data in SEC filings

Market cap

$649M

Revenue (TTM)

$0.00

Net income (TTM)

-$52.0M

EPS (TTM)

$-1.07

P/E ratio

—

Dividend yield

—

Free cash flow

-$49.5M

Cash

$28.1M

Total assets

$33.1M

Gross margin

—

52-week range

$2.37 – $7.11

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Amended charter or bylaws; Shareholder vote results Jul 6, 2026 8-K Director or officer change Jun 2, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Results of operations (earnings release); Director or officer change May 12, 2026 10-K/A Fiscal year ended 2025-12-31 Apr 30, 2026 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Regulation FD disclosure Apr 16, 2026 10-K Fiscal year ended 2025-12-31 Mar 24, 2026 8-K Results of operations (earnings release) Mar 24, 2026 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Director or officer change Oct 7, 2025 8-K Director or officer change Sep 11, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Entered a material agreement; Other events Jun 27, 2025 8-K Shareholder vote results Jun 6, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 10-K Fiscal year ended 2024-12-31 Mar 11, 2025 8-K Results of operations (earnings release) Mar 11, 2025 8-K Other events Feb 10, 2025 8-K Director or officer change Jan 10, 2025 8-K Director or officer change Dec 9, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Entered a material agreement Sep 27, 2024 8-K Director or officer change; Other events Aug 26, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Results of operations (earnings release) Aug 13, 2024 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Jul 29, 2024 8-K Regulation FD disclosure Jun 27, 2024 8-K Shareholder vote results Jun 6, 2024 10-Q Quarter ended 2024-03-31 May 9, 2024 8-K Results of operations (earnings release) May 9, 2024 10-K Fiscal year ended 2023-12-31 Mar 28, 2024 8-K Results of operations (earnings release) Mar 28, 2024 8-K Entered a material agreement; Terminated a material agreement; Results of operations (earnings release); Unregistered sale of equity; Regulation FD disclosure Feb 29, 2024 8-K Other events Dec 11, 2023 10-Q Quarter ended 2023-09-30 Nov 9, 2023 8-K Results of operations (earnings release) Nov 9, 2023